Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
Open Access
- 23 August 2010
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 448
- https://doi.org/10.1186/1471-2407-10-448
Abstract
Studies about the biology, treatment pattern, and treatment outcome of metastatic/recurrent neuroendocrine tumor (NET) have been few.Keywords
This publication has 31 references indexed in Scilit:
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II StudyJournal of Clinical Oncology, 2008
- Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasmsCancer, 2008
- Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumoursAnnals of Oncology, 2008
- Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumorsEndocrine-Related Cancer, 2007
- Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?Cancer Chemotherapy and Pharmacology, 2006
- Efficacy and Tolerability of Pegylated IFN-α in Patients with Neuroendocrine Gastroenteropancreatic CarcinomasJournal of Interferon & Cytokine Research, 2006
- Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapyLung Cancer, 2004
- Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1992
- Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid SyndromeNew England Journal of Medicine, 1983
- Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1980